​We are committed to serving patients with respiratory distress and making a positive impact in their lives!
May 15th, 2026
DDonovan B. Yeates, Ph.D. (Founder & CEO) presented the poster "AeroPulsR™: Predictable Pulmonary Aerosol Delivery of Complex Therapeutics in Critical Care" at the ATS Respiratory Innovation Summit (RIS) 2026. The presentation highlighted AeroPulsR™'s programmable aerosol delivery technology for predictable, high-dose pulmonary delivery of complex therapeutics across neonatal, pediatric, and adult critical care applications. The Respiratory Innovation Summit brings together innovators, clinicians, investors, and industry leaders to advance next-generation respiratory therapies.
May 10 th, 2026
Respiratory Drug Delivery (RDD®) 2026, Phoenix, Arizona • May 10–14, 2026
Donovan B. Yeates, Ph.D. (Founder & CEO) and Sai Siva Kare, Ph.D. showcased KAER Biotherapeutics' latest advances in programmable aerosol delivery at Respiratory Drug Delivery (RDD®) 2026. Donovan presented "A Programmable Aerosol Delivery Platform with Multi-Formulation Capability and High Aerosolization Rates," while KAER exhibited the AeroPulsR™ Programmable platform.
June 22nd, 2025
International Society for Aerosols in Medicine (ISAM) 2025 Congress Washington 22 - 25th June
Donovan B Yeates PhD (Founder & CEO) and Sai Siva Kare PhD presented - "AeroPulsR: High-Dose Therapeutic Aerosol Delivery for Pediatrics & Adults in ICU" at ISAM 2025. AeroPulsR was also exhibited.
June 16th, 2025
BIO International Convention 2025
Donovan B Yeates PhD (Founder & CEO) presented - " High-Dose Delivery of Inhaled Anti-Biotics, Anti-Infectives and Pulmonary Surfactant for Children and Adult Critical Care Patients" at BIO 2025. We look forward to partner with leading respiratory therpautic drug manufacturers.
May 16th, 2025
American Thoracic Society (ATS) Respiratory Innovation Summit (RIS) 2025
Donovan B Yeates PhD (Founder & CEO) presented – “AeroPulsR: High-Dose Therapeutic Aerosol Delivery for Pediatrics & Adults in ICU.”
Jan 22nd, 2025 PRESS RELEASE READ HERE
KAER Bio launches AeroPulsR high dose delivery system for critical care use
KAER Biotherapeutics has announced the launch of the AeroPulsR aerosol device for delivery of high doses of aqueous aerosols in critical care settings...
May 14th - 15th, 2025
Pharma Partnering Summing, San Diego, CA, USA 2025
Donovan B Yeates PhD (Founder & CEO) presented – “High Dose Aerosol Delivery of Complex Molecular Structures for Pediatric and Adult ICU patients with Respiratory Insufficiency.”
Feb 24th - 26th, 2025
Pharma R&D, 7th International Conference on PharmScience Research and Development
Donovan B Yeates PhD (Founder & CEO) presented – “Delivering Critical Care Respiratory Therapeutics as high concentration Aerosols Generated from Viscous and Complex Solutions.”
Feb 3rd - 4th, 2025
Drug Delivery Summit, San Diego, USA
Donovan B Yeates PhD (Founder & CEO) and Stephen Shrewsbury MD (Business & Scientific Advisor) showcased AeroPulsR and presented - "Respiraotry Critical Care: Generation and of Aerosols for Deep Lung Delivery."
Feb 26th - 28th, 2024
Pharma R&D, Boston, MD, USA
Donovan B Yeates PhD (Founder & CEO) presented - "Aerosol Delivery of Surfactant for ARDS."